Welcome to our dedicated page for Karyopharm Therapeutics news (Ticker: KPTI), a resource for investors and traders seeking the latest updates and insights on Karyopharm Therapeutics stock.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company focused on novel cancer therapies that target nuclear export dysregulation. Its lead product, XPOVIO (selinexor), is a first-in-class, oral exportin 1 (XPO1) inhibitor approved in the U.S. in multiple oncology indications and in various indications across more than 50 ex-U.S. territories and countries, according to company statements.
This news page aggregates company-issued updates and market disclosures related to Karyopharm. Readers can follow announcements on XPOVIO commercial performance, such as reported U.S. net product revenue and trends in license and royalty revenue from international partners, as described in the company’s earnings releases. The feed also covers progress in Karyopharm’s clinical pipeline, including multiple myeloma, endometrial cancer, myelofibrosis and diffuse large B-cell lymphoma (DLBCL).
Recent news has highlighted key milestones in late-stage development, including completion of enrollment in the Phase 3 SENTRY trial (XPORT-MF-034) in myelofibrosis and ongoing enrollment in the global Phase 3 XPORT-EC-042 trial in TP53 wild-type advanced or recurrent endometrial cancer. Company releases also describe Phase 2 data in heavily pretreated myelofibrosis patients and the design of additional studies such as SENTRY-2 and XPORT-MM-031 in multiple myeloma.
In addition to clinical and commercial updates, Karyopharm’s news includes financial results, preliminary revenue disclosures, strategic financing transactions involving term loans and convertible notes, and inducement equity awards granted under its inducement stock incentive plan. Investors and observers can use this page to review the company’s own descriptions of its operational progress, financing activities and anticipated clinical catalysts as reported in press releases and referenced in SEC filings.
Karyopharm Therapeutics (KPTI) reported Q3 2020 financial results, achieving $21.3 million in net product sales, a 15% increase from Q2, primarily driven by new multiple myeloma and DLBCL patient starts. The company presented positive top-line results from the Phase 3 SEAL study, showing XPOVIO's efficacy in treating dedifferentiated liposarcoma, with plans to submit a New Drug Application to the FDA in Q1 2021. Karyopharm expects ongoing revenue from XPOVIO to support operations through mid-2022, despite a net loss of $53.5 million for the quarter.
Karyopharm Therapeutics (Nasdaq: KPTI) reported positive top-line results from the Phase 3 SEAL study, indicating that XPOVIO® (selinexor) significantly increases progression-free survival (PFS) in patients with advanced unresectable dedifferentiated liposarcoma, showing a 30% reduction in disease progression risk compared to placebo. The study involved approximately 285 patients, and results will be presented at the CTOS Annual Meeting on November 20, 2020. Karyopharm plans to submit a New Drug Application to the FDA in Q1 2021, potentially positioning XPOVIO as the first oral, non-chemotherapy treatment for this condition.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) will announce its third quarter 2020 financial results on November 2, 2020. A conference call led by the management team will take place at 4:30 p.m. ET that same day to discuss the results and company updates. The company focuses on developing innovative cancer therapies, including its lead product XPOVIO (selinexor), which has received FDA approvals for multiple myeloma and diffuse large B-cell lymphoma. A Marketing Authorization Application for selinexor is also under review in Europe.
MediSpend announced that Karyopharm Therapeutics (NASDAQ: KPTI) has chosen its Transparency Solution to meet state and federal reporting regulations. Launched in October 2020, this SaaS-based platform collects, validates, and reports transfers of value to ensure compliance with transparency laws. Karyopharm sought advanced technology and advisory services from MediSpend to manage evolving regulations effectively. Karyopharm is known for its innovative cancer therapies, including the FDA-approved drug XPOVIO®.
Karyopharm Therapeutics (KPTI) announced an oral presentation at the ISIRV-AVG Virtual Conference discussing the Phase 2 clinical study of low-dose selinexor for severe COVID-19 patients. Despite the discontinuation of the trial due to not meeting primary endpoints for the overall population, encouraging results were seen in patients with low LDH/DD, showing a higher discharge rate by Day 14 (78.9% vs. 57.1%; p=0.029). The drug also demonstrated potential anti-inflammatory effects.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) has granted stock options for 122,300 shares to 17 new employees, effective September 30, 2020. Each option has an exercise price of $14.60, equal to the stock's closing price on that date. The options will vest over four years, with 25% vesting on the one-year anniversary of employment. Additionally, options will be fully exercisable under certain conditions related to employment termination. Karyopharm is known for its novel cancer therapies and its lead compound, XPOVIO®, has received FDA approvals for multiple indications.
Karyopharm Therapeutics (Nasdaq: KPTI) announced that four abstracts showcasing clinical data on XPOVIO (selinexor) will be presented at the ESMO Virtual Congress from September 19-21, 2020. Key findings include promising combination results of XPOVIO with pembrolizumab in metastatic melanoma, and with carboplatin and paclitaxel in advanced solid tumors. The data indicates significant clinical activity, suggesting potential for further exploration in solid tumors, enhancing Karyopharm's pipeline prospects.
Karyopharm Therapeutics (Nasdaq: KPTI) announced CEO Michael Kauffman's participation in upcoming investor conferences: Baird's 2020 Global Healthcare Conference on September 9 at 10:15 AM ET and Morgan Stanley's 18th Annual Global Healthcare Conference on September 15 at 5:00 PM ET. The events will feature live webcasts accessible via the company's investor section, with replays available for 90 days. Karyopharm is known for its innovative cancer therapies, particularly its lead drug, XPOVIO, which has received multiple FDA approvals for various cancer treatments.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced stock options for 29,600 shares granted to seven new employees as part of a recruitment incentive, with an exercise price of $15.21 per share. The options vest over four years, with 25% vesting on the one-year anniversary of employment. Notably, these options will be immediately exercisable if employment is terminated for 'good reason' or without 'cause' within a year following a change in control. Karyopharm focuses on innovative cancer therapies, including its lead compound, XPOVIO, which has received FDA approval for multiple myeloma and lymphoma.
Karyopharm Therapeutics (Nasdaq: KPTI) has appointed Christy J. Oliger to its Board of Directors. Oliger, previously the Senior VP of Genentech's Oncology Business Unit, brings over 25 years of experience in the biopharmaceutical sector. Her expertise is expected to aid in the development and commercialization of Karyopharm's lead product, XPOVIO, which is already FDA-approved for multiple indications. CEO Michael G. Kauffman emphasized her strategic value for expanding XPOVIO's reach to new patient populations. Oliger aims to contribute to the company's growth and enhance its impact on cancer treatment.
FAQ
What is the current stock price of Karyopharm Therapeutics (KPTI)?
What is the market cap of Karyopharm Therapeutics (KPTI)?
